Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and carboplatin in triple negative breast cancer
NCT02124902Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2014
- Primary completion
- Nov 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, carboplatin in triple-negative breast cancer (TNBC), sponsored by Washington University School of Medicine. Started Jul 2014; status: terminated.
02
Drugs
docetaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02124902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124902.